Change in the scope of the consolidation
Acquisitions
In 2018 DSM did not acquire any new businesses.
The PPAs for the 2017 acquisitions of Inner Mongolia Rainbow Biotechnology, Twilmij, BioCare Copenhagen and Amyris Brasil were finalized in 2018. In accordance with IFRS 3, the purchase price was allocated to identifiable assets and liabilities acquired. The PPA of Twilmij resulted in a reallocation of goodwill (-€31 million) to mainly other intangible assets for customer relations and the brand name. The PPA of the BioCare Copenhagen acquisition led to a reallocation of goodwill (-€21 million) to other intangible assets for technology and customer relations. The finalization of the PPA of Amyris Brasil resulted in recognition of an additional contingent consideration of €50 million. This was reallocated to intangible assets for customer relations, IP and goodwill.
The impact of the acquisitions on DSM's consolidated balance sheet (measured at the date of acquisition) is shown in the following table.
|
Acquisitions: finalization of PPA
|
Amyris Brasil
|
Twilmij
|
BioCare
|
Other
|
Total
|
|---|---|---|---|---|---|
|
Assets
|
|||||
|
Intangible assets
|
47
|
39
|
26
|
4
|
116
|
|
Property, plant and equipment
|
(3)
|
2
|
-
|
-
|
(1)
|
|
Other non-current assets
|
(13)
|
-
|
-
|
(2)
|
(15)
|
|
Receivables
|
-
|
-
|
2
|
-
|
2
|
|
Total assets
|
31
|
41
|
28
|
2
|
102
|
|
Non-controlling interests
and liabilities
|
|||||
|
Non-controlling interests
|
-
|
-
|
-
|
(1)
|
(1)
|
|
Non-current liabilities
|
(16)
|
10
|
6
|
1
|
1
|
|
Current liabilities
|
(2)
|
-
|
1
|
-
|
(1)
|
|
Total non-controlling interests and liabilities
|
(18)
|
10
|
7
|
-
|
(1)
|
|
Net assets
|
49
|
31
|
21
|
2
|
103
|
|
Consideration
|
50
|
-
|
-
|
-
|
50
|
|
Goodwill
|
1
|
(31)
|
(21)
|
(2)
|
(53)
|
|
Acquisition costs recognized in APM adjustments
|
1
|
-
|
-
|
3
|
4
|
Disposals
There were no material disposals in 2018.
Other changes
On 1 January 2018, DSM deconsolidated the Yantai Andre Pectin business, following developments in early January after the refusal of the other shareholders to transfer their shares to DSM despite an earlier agreement.